Bacterial Vaginosis Drug Market is expected to reach US$ 3.82 Billion by 2031

Prescription Drugs Segment to Bolster Bacterial Vaginosis Drug Market Growth During 2024–2031

According to our new research study on "Bacterial Vaginosis Drug Market Forecast to 2031 – Global Analysis – by Type, Route of Administration, Dosage Form, and Distribution Channel," the market was valued at US$ 2.15 billion in 2024 and is projected to reach US$ 3.82 billion by 2031; it is anticipated to record a CAGR of 8.3% from 2024 to 2031.

The report emphasizes the bacterial vaginosis drug market trends, along with drivers and deterrents affecting the market growth. The rising prevalence of bacterial vaginosis, and the increased focus on developing novel and targeted therapies are contributing to the growing bacterial vaginosis drug market size. However, the high recurrence rate and treatment adherence challenges hamper the market growth. Further, rising inclination toward microbiome therapies and probiotics are expected to emerge as new market trends in the coming years.

Bacterial Vaginosis Drug Market Share, by Region, 2023 (%)

Source: The Insight Partners Analysis

Rising Prevalence of Bacterial Vaginosis Bolsters Bacterial Vaginosis Drug Market Growth

Bacterial vaginosis is a common condition experienced by women of childbearing age, which is generally caused by changes in the normal bacterial flora of the vagina. Bacterial vaginosis is characterized by a decrease in Lactobacillus species and increase in anaerobic bacteria such as Ureaplasma urealyticum, Gardnerella vaginalis, Mobiluncus species, Mycoplasma hominis, and Prevotella species. Activities such as unprotected sexual intercourse and frequent douching further increase the risk of bacterial vaginosis. Common symptoms of the condition include abnormal vaginal discharge, odor, and itching. According to the European Journal of Obstetrics & Gynecology and Reproductive Biology article published in ScienceDirect Journal in 2023, the global prevalence of bacterial vaginosis ranges from 23% to 29%, and in pregnant women, it ranges from 11% to 49%. According to a report by Medscape in 2024, approximately one-third of adult women, i.e., ~22 million, in the US are affected by bacterial vaginosis every year, and 10 million women visit clinics for vaginal discharge. Bacterial vaginosis poses risks such as preterm labor, miscarriage, and increased susceptibility to HIV and other sexually transmitted infections. The increasing incidence of bacterial vaginosis, coupled with potential complications, encourages women to seek medical attention and pharmaceutical interventions, creating significant demand for effective drugs. The high chances of recurrence of bacterial vaginosis lead to the development of treatment regimens to prevent relapses. As healthcare access improves globally, especially in emerging markets, a larger number of women are now seeking treatment for bacterial vaginosis, driving the growth of the bacterial vaginosis drug market.

Bacterial Vaginosis Drug Market Report Scope:

The bacterial vaginosis drug market analysis has been carried out by considering the following segments: type, route of administration, dosage form, distribution channel, and geography. 

Based on type, the market is segmented into prescription drugs and over-the-counter drugs. The prescription drugs segment held a larger bacterial vaginosis drug market share in 2024. Bacterial vaginosis is a bacterial infection with common symptoms such as unusual vaginal discharge, odor, itching, and discomfort. Prescription medications are backed by a higher level of clinical support. These drugs are subjected to rigorous testing and clinical trials aimed at establishing their safety and efficacy, making them the standard of care for bacterial vaginosis. Healthcare professionals are more likely to prescribe prescription drugs after diagnosing the condition through clinical evaluation or laboratory testing. These factors create a stronger trust in prescription-based treatment.

Prescription treatments, including antibiotics such as metronidazole and clindamycin, are more effective in eradicating the root cause of the infection by targeting specific bacterial imbalances; both of these antibiotics can be administered orally or vaginally. Healthcare providers generally prefer these prescription drugs owing to their precision in treatment, reducing the likelihood of recurrence and complications such as pelvic inflammatory disease or infertility, which can result from untreated or mismanaged bacterial vaginosis. Advancements in drug formulations, including extended-release versions and more convenient topical treatments, have improved patient adherence and satisfaction. In January 2024, Organon introduced XACIATO (clindamycin phosphate) vaginal gel 2%, which is now available by prescription for the treatment of bacterial vaginosis

In terms of route of administration, the bacterial vaginosis drug market is categorized into oral, vaginal, and topical. The oral segment dominated the market in 2024. Oral drug delivery is a preferred and appropriate route of administration owing to convenience, enhanced treatment adherence, and drug formulation advancements. Oral medications, such as metronidazole and tinidazole, are increasingly preferred to treat conditions such as bacterial vaginosis, where treatment duration is often extended. Advancements in pharmaceutical technology have led to improved, more effective oral formulations with fewer side effects and better tolerability, making them a desirable choice for both patients and healthcare providers. In September 2017, the Food and Drug Administration (FDA) approved the first single-dose oral treatment secnidazole (Solosec, Symbiomix Therapeutics) for females with bacterial vaginosis. Similarly, in February 2022, Lupin Pharmaceuticals Inc. received the US FDA approval for its supplemental New Drug Application (sNDA). This approval allowed for the expanded use of SOLOSEC (secnidazole) in treating bacterial vaginosis in female patients aged 12 and older. The supplemental adolescent approval strengthens SOLOSEC’s position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both bacterial vaginosis and trichomoniasis.

In terms of dosage form, the bacterial vaginosis drug market is categorized into pills, creams, gel , solution/washes, and others. The pills segment dominated the market in 2024. Oral drug administration is easier for patients suffering from vaginosis compared to topical treatments. This ease of use encourages better treatment adherence, which is crucial for effective bacterial vaginosis treatment. The increasing number of treatment options available in the form of oral antibiotics, such as metronidazole (pill), is another factor benefiting the market for the pills segment. The drugs have proven efficacy in treating bacterial vaginosis and are often prescribed in pill form due to their reliable absorption and consistent therapeutic effect. Oral antibiotics are highly effective in targeting the bacteria responsible for bacterial vaginosis, making them a preferred choice for physicians and patients alike. With more women seeking out effective and simple solutions, oral medications, especially pills, have gained popularity because they provide a straightforward and less invasive treatment option compared to alternatives, including gels or creams.

In terms of distribution channel, the bacterial vaginosis drug market is categorized into hospital pharmacies, online pharmacies, and retail pharmacies. The hospital pharmacies segment dominated the market in 2024. Hospital pharmacies are a crucial part of healthcare, and they cater to a unique inpatient setting, facilitating the timely supply of crucial medications to patients. These facilities strive to maintain and enhance a patient’s medication management and maximize care quality. Hospital pharmacists serve as part of a patient-support system and are prepared to offer recommendations on adjunctive therapy if needed. As per the World Health Organization, they can interact more closely with prescribers and buyers to promote the rational use of drugs.

As hospitals are key healthcare providers for both primary and specialized care, they focus on being approachable to patients suffering from various health conditions, including bacterial vaginosis, facilitating better diagnosis, treatment, and drug management. Additionally, the growing awareness about bacterial vaginosis, coupled with improved diagnostic tools, has led to a higher number of patients seeking treatment for bacterial vaginosis, especially in hospital settings where advanced care is available. Hospital pharmacies cater primarily to patients undergoing treatments in the corresponding hospitals or those seeking prescription-based treatment for more severe cases of bacterial vaginosis.

Bacterial Vaginosis Drug Market Analysis: Based on Geography

The geographic scope of the bacterial vaginosis drug market report includes the assessment of the market performance in North America (US, Canada, and Mexico), Europe (Spain, UK, Germany, France, Italy, and Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and Rest of Asia Pacific), South & Central America (Brazil, Argentina, and Rest of South & Central America), and the Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa).   

European Journal of Obstetrics & Gynecology and Reproductive Biology, National Institutes of Health, Medscape, Government of Canada, UN World Population Prospects 2024, Eurostat, European Commission, Australian Government’s Department of Health and Aged Care, World Bank, and International Trade Administration are among the primary and secondary sources referred to while preparing the bacterial vaginosis drug market report.     

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com